Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2363066 Target Snapshot

3',5'-cyclic phosphodiesterase · PROTEIN FAMILY · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
17Compounds
6Assays
0Approved Drugs
16.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

3',5'-cyclic phosphodiesterase shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O76074. Start with cardiovascular disease, then reuse UniProt O76074 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cardiovascular disease, then reuse UniProt O76074 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
cardiovascular disease

3',5'-cyclic phosphodiesterase shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with cardiovascular disease because it currently carries approved-linked support. Linked drugs include DIPYRIDAMOLE, PENTOXIFYLLINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Protein anchor
cGMP-specific 3',5'-cyclic phosphodiesterase

cGMP-specific 3',5'-cyclic phosphodiesterase

Review this target as 3',5'-cyclic phosphodiesterase, mapped to UniProt O76074. ChEMBL maps the protein component as cGMP-specific 3',5'-cyclic phosphodiesterase. Sequence length is 875 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt O76074 Protein 875 aa
Open protein block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 3',5'-cyclic phosphodiesterase as ChEMBL target CHEMBL2363066, mapped to UniProt O76074. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
3',5'-cyclic phosphodiesterase
PROTEIN FAMILY · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2363066
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O76074
cGMP-specific 3',5'-cyclic phosphodiesterase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 3',5'-cyclic phosphodiesterase is the right protein anchor across sources, using UniProt O76074 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cardiovascular disease is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name3',5'-cyclic phosphodiesterase
Target TypePROTEIN FAMILY
OrganismHomo sapiens
UniProtO76074
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelcGMP-specific 3',5'-cyclic phosphodiesterase
UniProt AccessionO76074
Component TypeProtein
Sequence Length875 aa

cGMP-specific 3',5'-cyclic phosphodiesterase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as 3',5'-cyclic phosphodiesterase, mapped to UniProt O76074. ChEMBL maps the protein component as cGMP-specific 3',5'-cyclic phosphodiesterase. Sequence length is 875 aa.

Mapped IDO76074
Review name3',5'-cyclic phosphodiesterase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

3',5'-cyclic phosphodiesterase shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cardiovascular disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugDIPYRIDAMOLE
Linked drugPENTOXIFYLLINE
Approved-linked Approved
coronary artery disease
1 linked drug · 1 direct · 1 efficacy
Linked drugDIPYRIDAMOLE
Approved-linked Approved
Recurrent thrombophlebitis
1 linked drug · 1 direct · 1 efficacy
Linked drugDIPYRIDAMOLE
Approved-linked Approved
stroke
1 linked drug · 1 direct · 1 efficacy
Linked drugDIPYRIDAMOLE
Late clinical Phase III
COVID-19
2 linked drugs · 2 direct · 2 efficacy
Linked drugDIPYRIDAMOLE
Linked drugPENTOXIFYLLINE
Late clinical Phase III
heart disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugDIPYRIDAMOLE
Linked drugPENTOXIFYLLINE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cardiovascular disease because it currently carries approved-linked support. Linked drugs include DIPYRIDAMOLE, PENTOXIFYLLINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecardiovascular disease
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC5016.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5081214 10.0 IC50 0.1 Preclinical
CHEMBL5080391 9.9 IC50 0.1259 Preclinical
CHEMBL5087564 9.8 IC50 0.1585 Preclinical
CHEMBL5094110 9.6 IC50 0.2512 Preclinical
CHEMBL5076558 9.5 IC50 0.3162 Preclinical
CHEMBL5086895 9.5 IC50 0.3162 Preclinical
CHEMBL5078680 9.0 IC50 1.0 Preclinical
CHEMBL5088742 9.0 IC50 1.0 Preclinical
CHEMBL5434573 6.48 IC50 330.0 Preclinical
CHEMBL92216 6.0 IC50 1000.0 Preclinical
Distribution

pChEMBL Value Distribution

0
5.0
2
5.5
2
6.0
0
6.5
0
7.0
0
7.5
0
8.0
0
8.5
2
9.0
5
9.5
pChEMBL
Assay Landscape

Assay Landscape

6
Total Assays
14
Tested Compounds
2
Assay Types
Binding — 5 assays, 14 compounds
BAO Format Assays Compounds Avg pChEMBL
protein format 4 6 5.4
cell-based format 1 8 9.5
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
protein format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine